14 August 2020: Database Analysis
The Role of Chemotherapy in Extraskeletal Osteosarcoma: A Propensity Score Analysis of the Surveillance Epidemiology and End Results (SEER) Database
Lin Qi 12ABCDEF , Lu Wan 123BC , Xiaolei Ren 12EF , Wenchao Zhang 12E , Chao Tu 12ADE* , Zhihong Li 12ADG*DOI: 10.12659/MSM.925107
Med Sci Monit 2020; 26:e925107
Supplementary Table 3 Cox regression models for OS in patients with ESOS in the PSM cohort.
| Characteristic | Model 1* (Matched cohort) | Model 2** (Matched cohort) | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Chemotherapy | No | Reference | NA | Reference | NA |
| Yes | 0.804 (0.552–1.172) | 0.257 | 0.814 (0.557–1.189) | 0.287 | |
| Age (year) | Reference | NA | Reference | NA | |
| ≥60 | 1.782 (1.187–2.676) | 0.005 | 2.062 (1.304–3.259) | 0.002 | |
| Gender | Male | Reference | NA | ||
| Female | 0.905 (0.583–1.403) | 0.654 | |||
| Race | White | Reference | NA | Reference | NA |
| Black | 0.899 (0.486–1.663) | 0.735 | 0.962 (0.513–1.805) | 0.905 | |
| Other | 0.746 (0.286–1.946) | 0.551 | 0.773 (0.288–2.079) | 0.611 | |
| Insurance type | Insured | Reference | NA | ||
| Any medicaid | 1.661 (0.726–3.798) | 0.229 | |||
| Unknown | 1.915 (0.811–4.525) | 0.138 | |||
| Marital status | Single | Reference | NA | Reference | NA |
| Widowed/divorced | 0.927 (0.506–1.698) | 0.806 | 0.954 (0.507–1.795) | 0.884 | |
| Married | 0.834 (0.482–1.442) | 0.516 | 0.862 (0.484–1.534) | 0.612 | |
| Unknown | 2.004(0.698–5.753) | 0.197 | 2.079 (0.655–6.601) | 0.214 | |
| Year of diagnosis | 1976 to 1985 | Reference | NA | ||
| 1986 to 1995 | 1.357 (0.644–2.863) | 0.422 | |||
| 1996 to 2005 | 0.763 (0.376–1.546) | 0.453 | |||
| 2006 to 2016 | 1.535 (0.588–4.005) | 0.382 | |||
| Primary site | Extremity | Reference | NA | Reference | NA |
| Trunk | 2.148 (1.319–3.495) | 0.002 | 2.329 (1.389–3.904) | 0.001 | |
| Visceral | 2.521 (1.481–4.292) | 0.001 | 2.767 (1.577–4.853) | ||
| Other | 0.881 (0.452–1.715) | 0.709 | 0.951 (0.477–1.889) | 0.883 | |
| Grade | Grade I/II | Reference | NA | Reference | NA |
| Grade III/IV | 1.015 (0.445–2.319) | 0.971 | 1.061 (0.452–2.486) | 0.893 | |
| Unknown | 0.886 (0.366–2.144) | 0.788 | 0.903 (0.365–2.237) | 0.826 | |
| Stage | Localized | Reference | NA | Reference | NA |
| Regional | 1.757 (1.105–2.793) | 0.017 | 1.762 (1.092–2.842) | 0.021 | |
| Distant | 2.626 (1.512–4.561) | 0.001 | 3.221 (1.773–5.849) | ||
| Unstaged | 1.585 (0.702–3.581) | 0.268 | 1.582 (0.652–3.838) | 0.311 | |
| Tumor size (mm) | Reference | NA | Reference | NA | |
| ≥73 | 4.571 (2.952–7.705) | 4.967 (3.132–7.878) | |||
| Radiation | Yes | Reference | NA | ||
| No | 0.641 (0.401–1.025) | 0.063 | |||
| Surgery | Yes | Reference | NA | Reference | NA |
| No | 3.957 (2.269–6.902) | 4.345 (2.432–7.763) | |||
| CI – confidence interval; ESOS – extraskeletal osteosarcoma; NA – not applicable; HR – hazard ratio; mm – millimeter; OSM – osteosarcoma; PSM – propensity score matched. * Multivariable Cox regression adjusted for chemotherapy, age, race, marital status, primary site, grade, stage, tumor size and surgery in the matched cohort. ** Multivariable Cox regression adjusted for all characteristics in the study in the matched cohort. | |||||